| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14656560903215871 |
| P698 | PubMed publication ID | 19827991 |
| P2093 | author name string | G M Andreozzi | |
| P2860 | cites work | Peripheral arterial disease detection, awareness, and treatment in primary care | Q28216456 |
| Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis | Q33535917 | ||
| Pharmacokinetics of L-carnitine | Q34536074 | ||
| Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation | Q34537719 | ||
| L-propionyl-carnitine protects tissues from ischaemic injury in an 'in vivo' human ischaemia-reperfusion model | Q34547017 | ||
| Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). | Q34586454 | ||
| Exercise training for claudication | Q35023647 | ||
| Carnitine and peripheral arterial disease | Q35980297 | ||
| Exercise therapy and the additional effect of supervision on exercise therapy in patients with intermittent claudication. Systematic review of randomised controlled trials | Q36747636 | ||
| Chronic changes in skeletal muscle histology and function in peripheral arterial disease | Q41090368 | ||
| Free radical scavenging is involved in the protective effect of L-propionyl-carnitine against ischemia-reperfusion injury of the heart. | Q41130658 | ||
| The evidence for exercise-induced inflammation in intermittent claudication: should we encourage patients to stop walking? | Q41728180 | ||
| Propionyl-L-carnitine | Q41735042 | ||
| The fate of the claudicant--a prospective study of 1969 claudicants | Q41788501 | ||
| Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication | Q43623823 | ||
| Effects of ischaemic stress on leukocyte activation processes in patients with chronic peripheral occlusive arterial disease: role of L-propionyl carnitine administration. | Q43760930 | ||
| Carnitine inhibits arachidonic acid turnover, platelet function, and oxidative stress | Q44185602 | ||
| Abnormal mitochondrial respiration in skeletal muscle in patients with peripheral arterial disease | Q44618458 | ||
| Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial | Q44961239 | ||
| Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease | Q46576045 | ||
| Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication | Q46719211 | ||
| Mortality over a period of 10 years in patients with peripheral arterial disease | Q46786119 | ||
| Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. | Q46918811 | ||
| Effect of propionylcarnitine on changes in endothelial function and plasma levels of adhesion molecules induced by acute exercise in patients with intermittent claudication | Q46976511 | ||
| Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine. | Q52192914 | ||
| Response to exercise rehabilitation in smoking and nonsmoking patients with intermittent claudication. | Q53354432 | ||
| European multicenter study on propionyl-L-carnitine in intermittent claudication. | Q53538324 | ||
| The borrowing-lending hemodynamic phenomenon (hemometakinesia) and its therapeutic application in peripheral vascular disturbances. | Q53799409 | ||
| Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease | Q58421063 | ||
| Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: A functional, histologic, and NMR spectroscopic study | Q59157224 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | intermittent claudication | Q1097957 |
| claudication | Q2888709 | ||
| P304 | page(s) | 2697-2707 | |
| P577 | publication date | 2009-11-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Propionyl l-carnitine: intermittent claudication and peripheral arterial disease | |
| P478 | volume | 10 |
| Q64097026 | Association of moderately elevated trimethylamine N-oxide with cardiovascular risk: is TMAO serving as a marker for hepatic insulin resistance |
| Q34772905 | Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. |
| Q57809184 | Oxidative Stress and Arterial Dysfunction in Peripheral Artery Disease |
| Q37869187 | Pharmacological effects and clinical applications of propionyl-L-carnitine. |
| Q45061214 | Plasma pharmacokinetics and gastrointestinal transit of a new propionyl-L-carnitine controlled release formulation. |
| Q24201080 | Propionyl-L-carnitine for intermittent claudication |
| Q37977148 | The effect of nitric-oxide-related supplements on human performance. |
| Q37366244 | The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation |
Search more.